Pain Therapeutics Resumes Responsibility for REMOXY AUSTIN,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pain Therapeutics Resumes Responsibility for REMOXY

AUSTIN, Texas, April 21, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE ) today reported it had recently resumed responsibility for REMOXY ® under the terms of a letter agreement with Pfizer. The letter agreement was entered into within the scope of the previously disclosed provisions of the Collaboration Agreement between the two companies relating to the return of REMOXY.

Pfizer has started to transfer to Pain Therapeutics documents, data and regulatory responsibilities related to REMOXY. The two companies have agreed to implement a detailed transition plan involving an orderly transfer of a large amount of data, materials, capital equipment and other assets related to REMOXY. Pain Therapeutics expects the transition will be substantially completed in Q2 2015.

"We're excited REMOXY is home again," said Remi Barbier, Chairman, President & CEO. "We're now reviewing a lot of new information, including results of a Drug Likeability Study. We look forward to communicating with shareholders our findings in the weeks ahead, after we're done validating key clinical data and development timelines."

About REMOXY ®

Our lead drug candidate, REMOXY Extended-Release Capsules CII, is an oral, twice-a-day formulation of oxycodone for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. We specifically developed REMOXY to discourage certain common methods of drug tampering and misuse. We own world-wide commercial rights to this New Drug Application (NDA) stage drug. The REMOXY NDA is supported by multiple clinical trials, including a successful Phase III efficacy program that was conducted under a Special Protocol Assessment.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drugs. The FDA has not approved our drug candidates for commercial sale. For more information, please visit www.paintrials.com .

Note Regarding Forward-Looking Statements : This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, potential resubmission of an NDA for REMOXY with the U.S. Food and Drug Administration, or FDA and statements relating to Pfizer's return to us of rights to REMOXY, including data related to REMOXY, in connection with the termination of our Collaboration Agreement with Pfizer. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in Pfizer's return of REMOXY to us in connection with the termination of the Collaboration and difficulties or delays in preparing for potential submission of an NDA for REMOXY with the FDA and in obtaining regulatory approval of REMOXY. For further information regarding these and other risks related to our business, investors should consult our filings with the U.S. Securities and Exchange Commission.

Peter S. Roddy Vice President and Chief Financial Officer Pain Therapeutics, Inc. (512) 501-2450

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 160

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 297

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 308

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 304

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 85

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 85

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

The Booming Ethylene Vinyl Acetate Market: Insights and Trends

Updated Category News Views 114

Understanding the Growth of the Ethylene Vinyl Acetate Market As we delve into the dynamic landscape of the Ethylene Vinyl Acetate (EVA) market, it's clear that the demand for sustainable solutions is reshaping this sector. Recently valued at USD 11.0 billion, the market is projected to reach an impressive USD 19.2 billion by 2032, reflecting a compound annual growth rate...

Continue Reading
FETV Lassoing Nostalgia with 'Rawhide' Marathon

Updated Category News Views 35

FETV Brings 'Rawhide' Back for a July 4th Ride If anybody still had doubts about classic TV riding back into our living rooms and kicking up dust, FETV's got a surprise for them. This Independence Day, FETV's all geared up to bring the legendary western series, Rawhide, galloping back onto our screens. A weekend full of cattle drives and cowboy grit is exactly the kind of...

Continue Reading
China-Pakistani Lab Aims to Tackle Earthquake Disasters

Updated Category News Views 29

When the ground decides to play havoc, it takes a teamwork of the ages to put things back together. The China-Pakistan Belt and Road Joint Laboratory on Smart Disaster Prevention has taken on the task of preventing such chaos, especially for regions that flirt regularly with disaster, like Pakistan. From Surviving to Saving The memory of the 7.8-magnitude quake that...

Continue Reading
Investors Alert: Charter Communications Faces Legal Scrutiny

Updated Category News Views 149

Legal Concerns Surrounding Charter Communications Shamis & Gentile, P.A. has initiated an investigation into possible claims on behalf of investors of Charter Communications, Inc. (CHTR). This inquiry aims to assist those who may have suffered losses due to the actions of the company and its executives. Understanding the Investigation Investors in Charter Communications...

Continue Reading
Bumble's Options Activity: Insights and Market Trends

Updated Category News Views 336

Understanding Bumble's Recent Options Activity Recent analyses indicate that substantial financial entities are making bold moves in the options market surrounding Bumble Inc (NASDAQ: BMBL). A deep dive into options trading patterns reveals noteworthy insights about trader sentiment and market expectations. Analyzing Trader Sentiment The current options trades showcase a...

Continue Reading